Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation <i>in vitro</i> and sensitize tumors to doxorubicin <i>in vivo</i>
Holly K. Koblish(Wilmington University), Anna C. Maroney(AbbVie (United States)), Louis V. LaFrance(Johnson & Johnson (United States)), Pierre Raboisson(Johnson & Johnson (United States)), Raul R. Calvo(Johnson & Johnson (United States)), Bruce Grasberger(Johnson & Johnson (United States)), Joan M. Gushue(Johnson & Johnson (United States)), Juan Marugán(National Institutes of Health), Kristi Leonard(Johnson & Johnson (United States)), Christopher J. Molloy(Johnson & Johnson (United States)), Tianbao Lu(Johnson & Johnson (United States)), Robert R. Donatelli(Johnson & Johnson (United States)), Dana L. Johnson(Johnson & Johnson (United States)), Karen L. Milkiewicz(Johnson & Johnson (United States)), Daniel J. Parks(Johnson & Johnson (United States)), Carol F. Franks(Johnson & Johnson (United States)), Rose Tominovich(Johnson & Johnson (United States)), Shuyuan Zhao(Johnson & Johnson (United States)), Maxwell D. Cummings(Johnson & Johnson (United States))
Cited by 164
Related Papers
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
|Nature|2012|1.8k
Discovery and Cocrystal Structure of Benzodiazepinedione HDM2 Antagonists That Activate p53 in Cells
|Journal of Medicinal Chemistry|2005|430
Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2
|ACS Medicinal Chemistry Letters|2012|377
Motoneuron Apoptosis Is Blocked by CEP-1347 (KT 7515), a Novel Inhibitor of the JNK Signaling Pathway
|Journal of Neuroscience|1998|293